← back to search

Mariana Chávez‐MacGregor

The University of Texas MD Anderson Cancer Center · US
Area of research
Cancer Research · Oncology
Research interest
Research interests include Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Breast Lesions and Carcinomas, and HER2/EGFR in Cancer Research.
h-index
53
citations
14,251
works
317
NIH funding
primary concept
Medicine
email

Recent publications

6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
The Breast 2024cited by 184position: middledoi
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Journal of Clinical Oncology 2024cited by 171position: middledoi
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
Journal of Clinical Oncology 2024cited by 61position: middledoi
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline
JCO Global Oncology 2024cited by 44position: middledoi
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Journal of Clinical Oncology 2024cited by 17position: firstdoi
Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer
Journal of Clinical Oncology 2023cited by 42position: middledoi
Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
Journal of Clinical Oncology 2022cited by 172position: middledoi
Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System
Annals of Surgical Oncology 2021cited by 17position: middledoi
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
Journal of Clinical Oncology 2020cited by 1,470position: middledoi
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update
Archives of Pathology & Laboratory Medicine 2020cited by 363position: middledoi
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Breast Cancer Research 2019cited by 227position: middledoi
Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Journal of Clinical Oncology 2019cited by 66position: middledoi
Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ
Annals of Surgical Oncology 2016cited by 267position: middledoi
Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ
Practical Radiation Oncology 2016cited by 216position: middledoi
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer
JAMA Oncology 2016cited by 187position: middledoi
Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer
Annals of Surgical Oncology 2014cited by 610position: middledoi
Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer
International Journal of Radiation Oncology*Biology*Physics 2014cited by 486position: middledoi
Frequency of mesenchymal‐epithelial transition factor gene (<i>MET</i>) and the catalytic subunit of phosphoinositide‐3‐kinase (<i>PIK3CA</i>) copy number elevation and correlation with outcome in patients with early stage breast cancer
Cancer 2012cited by 57position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Meena S. Moran · University of Colorado Denver4 papers (2014–2016)Monica Morrow · Kettering University4 papers (2014–2016) · 4 papers (2014–2016) · 4 papers (2014–2016)Nehmat Houssami · Cancer Council Australia4 papers (2014–2016)Janet K. Horton · G1 Therapeutics (United States)4 papers (2014–2016)Stuart J. Schnitt · Harvard University4 papers (2014–2016)Daniel F. Hayes · Michigan United3 papers (2020–2023)Kimberly H. Allison · Stanford Medicine3 papers (2020–2023)Hope S. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center3 papers (2022–2024)Armando E. Giuliano · Shantou University Medical College3 papers (2014–2023)Gabriel N. Hortobágyi · The University of Texas MD Anderson Cancer Center3 papers (2012–2024)Lisa M. McShane · National Cancer Institute2 papers (2020–2020)Sunil R. Lakhani · Sullivan Nicolaides Pathology2 papers (2020–2020)Lawrence J. Solin · Einstein Medical Center Philadelphia2 papers (2016–2016)Priyanka Sharma · Assam Agricultural University2 papers (2023–2024)Lisa A. Carey · University of North Carolina at Chapel Hill2 papers (2020–2020)Véronique Dièras · Centre Eugène Marquis2 papers (2022–2024)Mitch Dowsett · Breast Cancer Now2 papers (2020–2020)Tracey Weisberg · Maine Medical Center2 papers (2020–2020)